TNFSF10 and hepatocellular carcinoma: To further explore the mechanisms that might be involved in the anti-HCC therapeutic effects of the two tested treatment approaches, we examined the apoptotic changes both in vitro on HuH7 cells and in vivo on the tumor tissues that were collected 3 days after the last treatment dose with either Ad-ΔB or Ad-ΔB/TRAIL + Ad-ΔB/IL-12 combination therapy.